Finding the best dose of tafenoquine to cure malaria caused by Plasmodium vivax in Southeast Asia
Official title: Optimizing the dose of tafenoquine for the radical cure of Plasmodium vivax malaria in Southeast Asia
Funded at University of Oxford · NIH-10925296 · Data updated 2026-11-12
This study is looking to find the best dose of tafenoquine, a medicine for treating malaria, especially for kids and pregnant women, to help prevent the illness from coming back and make it easier for patients to stick to their treatment.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oxford NIH-funded |
| Lab location | 1 site (Oxford, United Kingdom) |
| Project start | September 8, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $1,045,386 |
| NIH project number | 5U01AI165321-02 |
| Project ID | NIH-10925296 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Plasmodium vivax malaria, particularly children and pregnant women in Southeast Asia.
✕Less likely to help
Patients with malaria caused by other strains or those who have contraindications to tafenoquine may not benefit from this research.
What this research studies
This research aims to optimize the dosage of tafenoquine, a medication used to treat malaria caused by Plasmodium vivax, which is prevalent in Southeast Asia. The study will analyze data from previous clinical trials to determine the most effective dose that can prevent relapses of malaria, particularly in vulnerable populations such as children and pregnant women. By focusing on a single-dose treatment, the research seeks to improve patient compliance and health outcomes. Participants may be involved in trials assessing different doses to find the optimal amount for effective treatment.
Why it matters
Potential benefit: If successful, this research could lead to a more effective single-dose treatment for malaria, significantly reducing the incidence of relapses and improving health outcomes for patients.
How similar studies have gone: Previous studies have shown that optimizing drug dosages can significantly improve treatment outcomes, suggesting that this approach may yield beneficial results.
Where this research is happening
-
University of Oxford
Oxford, United Kingdom Active
Researchers
- Principal investigator: Chu, Cindy S — University of Oxford
- Study coordinator: Chu, Cindy S
Related research
Other NIH-funded projects on the same topics.
-
Digital malaria surveillance in Ethiopia to improve outbreak detection
A collaboration to add a malaria-specific digital module to an existing surveillance system in Africa to help detect and respond to outbreaks faster.
-
Cross-sector partnership uses digital malaria surveillance in Ethiopia
A US-based team will adapt and test a digital malaria surveillance module in SORMAS to help detect and respond to malaria outbreaks in Ethiopia.
-
Malaria control project in Western Kenya to reduce illness and deaths
A large, multi-year effort in western Kenya will help track malaria spread and test ways to prevent transmission so fewer people get sick or die.
-
Optimizing tafenoquine dose to prevent relapse of vivax malaria in Asia
A study tests the best tafenoquine dose to prevent P. vivax malaria relapse in people in East Asia and Oceania.
-
Optimizing tafenoquine dose to prevent P. vivax malaria relapses in Asia
A study to find the best single-dose tafenoquine amount to prevent relapse of P. vivax malaria in people in East Asia and Oceania.
-
Severe malaria and brain risk in children
This grant studies how severe malaria in young children can affect brain development and long-term thinking and behavior, with a focus on kids in Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.